Not much to go on, it's true. The low profile of the Zeiss...

Not much to go on, it's true. The low profile of the Zeiss collaboration in the assignment of funding is both reassuring and a bit scary: it seems like it's now up to Zeiss to move things along, which means limited funding/work from Optiscan is now needed but also means we have little control over how things proceed (the past bottlenecks seem to have been largely technical, hence our problem, I expect the future ones to be in product finalisation and marketing and sales). There's not much to be said about CellLive; I assume information about sales will be in the annual report. I was told they only need to sell around 1.5 systems a month to cover operating costs, so even a small pickup here might be significant. And the other products are still in the lab.